Last edition
News about "VectorY Therapeutics "
VectorY Doses First Patient in Phase I/II PIONEER-ALS Trial of TDP-43 Targeting Therapy VTx-002
VectorY initiates clinical evaluation of VTx-002, a first-in-class vectorised antibody therapy targeting TDP-43 pathology in ALS, with first patient dosed at Mass General Brigham.
VectorY Therapeutics | 11/02/2026 | By News Bureau
VectorY Welcomes Jim Scibetta as New CEO
Scibetta brings more than 20 years of executive leadership experience, having built earlier stage companies focused on developing novel therapeutics for high unmet medical needs into mature biotechnology companies.
VectorY Therapeutics | 17/12/2024 | By Aishwarya | 337
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy